Innate immune signaling and sex differences contribute to neurocognitive impairment,

neuroinflammation, and mitochondrial rewiring in a mouse model of Gulf War illness

Joshua D. Bryant[1], Maheedhar Kodali[2], Bing Shuai[2], Saeed S. Menissy[1], Paige J. Graves[1], Ashok

K. Shetty[2], Laura Ciaccia West[1*], and A. Phillip West[1*]

[1]Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M

University Health Science Center, Bryan, Texas, USA

[2]Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, College of

Medicine, Texas A&M University Health Science Center, College Station, Texas, USA

*Correspondence to: lwest@tamu.edu and awest@tamu.edu

Abstract

Gulf War Illness (GWI) is a chronic, multi-symptom disorder affecting approximately 30

percent of the nearly 700,000 veterans of the 1991 Persian Gulf War. Recent studies have revealed

that GWI-related chemical (GWIC) exposure promotes immune activation and metabolic rewiring,

which correlate with neurocognitive impairments and other symptoms of GWI. However, the

molecular mechanisms and signaling pathways linking GWIC to inflammation, metabolic

alterations, and neurological symptoms remain unclear. Mitochondrial dysfunction has been

documented in veterans with GWI and rodent models, and because mitochondria are key immune

regulators, we hypothesized that alterations to mitochondria-immune crosstalk could contribute to

the development of GWI-related symptoms. Here we show that acute exposure of murine

macrophages to GWIC alters mitochondrial respiration and potentiates innate immune signaling

and inflammatory cytokine secretion. Using an established mouse model of GWI, we report that

neurobehavioral changes, neuroinflammation, and mitochondrial protein rewiring are attenuated

in mice lacking the cyclic GMP-AMP synthase (cGAS)-Stimulator of Interferon Genes (STING)

and NOD-, LRR- or pyrin domain-containing protein 3 (NLRP3) innate immune pathways.

Finally, we report sex differences in response to GWIC, with female mice showing more

pronounced cognitive impairment, neuroinflammation, and mitochondrial protein alterations in the

brain compared to male mice. Our results provide novel information on sex differences in this

model and suggest that STING and NLRP3 are key mediators of the cognitive impairment,

inflammation, and mitochondrial dysfunction observed in GWI.

Keywords

Gulf War Illness; Mitochondrial Dysfunction; Innate Immune Signaling; Sex Differences;

Memory Impairment; Neuroinflammation

1. Introduction

Gulf War illness (GWI) is a chronic, multi-symptom disorder affecting approximately 25 to 32

percent of the nearly 700,000 veterans of the 1991 Persian Gulf War (PGW-1). Predominantly

characterized by brain-related problems including learning and memory deficits, depression, and

anxiety, GWI has been linked to synergistic exposure to chemicals including the nerve gas

prophylactic pyridostigmine bromide (PB), a reversible acetylcholinesterase inhibitor, and

permethrin (Per), an insecticide[1,2].

Research over the past few decades has uncovered mechanisms by which exposure to GWI-

related chemicals (GWIC) cause GWI pathology and symptoms. Normal function of the brain and

nervous system requires significant cellular energy, which is generated within cells by

mitochondria. GWIC exposure enhances reactive oxygen species (ROS) production and oxidative

stress[3], which may contribute to a vicious cycle of mitochondrial dysfunction (MD) by damaging

mitochondrial DNA (mtDNA) and oxidative phosphorylation (OXPHOS) proteins to further

augment ROS and trigger progressively increasing mitochondrial stress. Multiple studies have

documented MD in both human GWI patients[4,5,6] and in murine models of GWI[3,7,8,9]. Moreover,

clinical manifestations of GWI resemble those identified in Chronic Fatigue Syndrome (CFS),

which has been linked with MD[5,10].

Immune system alterations have also been associated with GWI pathology. Studies of GWI

patients have revealed immune changes, including increases in inflammatory cell types[11–13],

heightened production of proinflammatory cytokines[11,14–16], and transcriptional profiles that

resemble those observed in autoimmune disorders[17]. Parallel immune alterations have also been

observed in rodent models of GWI, with increases in proinflammatory cytokines seen in the

hippocampi of GWIC-exposed rats[3] and in the brains and serum of GWIC-exposed mice[9,18].

However, the role of the innate immune system in GWI pathology, and specifically the

identification of signaling cascades responsible for proinflammatory cytokine induction in animal

models and Veterans with GWI, remains uncharacterized.

Several GWI studies have demonstrated MD and inflammation contemporaneously,

suggesting an interaction between these two disease mechanisms[19]. Indeed, in addition to their

well-appreciated roles in cellular metabolism and apoptosis, mitochondria are key immune

regulators, impacting many aspects of signaling and effector responses in both the innate and

adaptive immune system[20]. MD and mtDNA damage can trigger a wide range of inflammatory

responses that have been implicated in immune-mediated pathology[21].

Based on evidence of MD and inflammation in GWI, and on the documented link between

the two, we hypothesized that exposure to GWIC might alter mitochondria-innate immune

crosstalk, contributing to inflammatory responses that exacerbate neuropathology and cognitive

symptoms of GWI. To test this hypothesis, we employed an established mouse model of GWI in

which mice are exposed to the GWIC by intraperitoneal injection for a period of 10 days,

developing cognitive impairment and neuroinflammation beginning at 5 months post-exposure[22–

24]. In our study, we employed a longitudinal analysis regimen, performing neurocognitive tests at

both 5 months and 12 months after acute exposure to GWIC, followed by analysis of mitochondrial

protein expression and neuroinflammation in the brain at the terminal timepoint. We used both

male and female mice in these experiments to evaluate sex-dependent effects of GWIC, as there is

evidence that GWI can be more severe in women[25]. To examine the acute effects of GWIC

exposure on metabolism and cell-intrinsic immune responses, we performed a series of *in vitro*

experiments using bone marrow-derived macrophages. And finally, we applied this GWIC-

exposure model to C57BL/6 genetic knockouts lacking key innate immune sensors that interface

with mitochondria and cellular metabolism to evaluate the contributions of these inflammatory

signaling pathways to development of GWI pathology. Our results provide important new

information on sex differences in GWI-related pathology and reveal that innate immune signaling

contributes to neurocognitive impairment, neuroinflammation, and mitochondrial rewiring in a

preclinical model of GWI.

2. Materials and Methods

2.1 Animals, study design, and Gulf War chemical agents

All C57BL/6J wild-type (WT) mice were purchased directly from Jackson Laboratories and

allowed to acclimate in the animal facility for 2-4 weeks, or bred in-house. Breeding pairs of NLR

Family Pyrin Domain Containing 3 null (NLRP3$^{-/-}$) (JAX strain 021302) and Stimulator of

Interferon Genes null (STING$^{gt/gt}$) (JAX strain 017537) mice were purchased from Jackson

Laboratories and bred to generate sufficient mice for all experiments. Mice were 8-10 weeks of

age upon exposure to GWIC.

Briefly, mice were randomly assigned to treatment cohorts: DMSO (vehicle control; 15

mice per sex for WT mice, 6 mice per sex for NLRP3$^{-/-}$ and STING$^{gt/gt}$ null mice) or GWIC (15

mice per sex for WT, NLPR3 null, and STING$^{gt/gt}$ mice). Mice then underwent an exposure

regimen of daily peritoneal injections of 50 microliters of DMSO alone for DMSO cohorts or 50

microliters of GWIC (0.7 mg/kg of PB and 200 mg/kg of Per) dissolved in DMSO for GWIC

cohorts. Five months after exposure, 6-10 randomly selected mice from DMSO-treated WT and

GWIC-treated WT, NLRP3$^{-/-}$, and STING$^{gt/gt}$ cohorts and all DMSO-treated NLRP3$^{-/-}$ and

STING$^{gt/gt}$ mice were subjected to neurobehavioral tests as described below. Twelve months after

exposure, mice that were behaviorally tested at five months were retested, and then all mice were

sacrificed for tissue processing or immunohistochemical analysis.

The Animal Care and Use Committee (IACUC) of the Texas A&M University College of

Medicine, which ensures compliance with all applicate federal and state regulations for the

purchase, transportation, housing, and ethical use of animals for research, has approved all

experiments performed in this study. The euthanasia methods employed in the study were

consistent with the recommendations of the American Veterinary Medical Association (AVMA).

Pyridostigmine bromide (99.9% purity) was purchased from Selleckchem (catalog number

HY-B0887) and permethrin (>98% purity) was purchased from MedChemExpress (catalog

number S1608).

2.2. Behavioral tests for analyses of cognitive and mood function

2.2.1. Object location test (OLT)

The object location test (OLT) involved three sequential trials (Figure 1A top panel): in the first

trial, termed the habituation trial, the mouse was placed at the corner of an empty open field

apparatus and allowed to freely explore for five minutes; in the second trial ("sample trial"), which

took place twenty minutes after the first trial, the mouse was placed in the corner of the same open

field apparatus, which now contained two identical objects placed on opposite sides of the box,

and allowed to free explore for five minutes; and in the third, "test" trial, after an inter-trial interval

of 20 minutes (5 months post-exposure) or 2 hours (12 months post-exposure), the mouse was

placed in the corner of the open field apparatus, with one of the objects remaining in its original

location and the other object moved to a novel location. The apparatus was cleaned with 70%

ethanol and allowed to air-dry prior to the commencement of each trial. The movement of the

mouse in the sample and test trials was continuously video-tracked using the Noldus Ethovision

XT program; the nose-point of the mouse coming within 2 cm of an object was recorded by the

software as object exploration. Data on time spent exploring both objects, total distance traveled,

and velocity of movement during these trials were collected. Percent time spent with the object in

a novel location was calculated as total time exploring this object divided by total time exploring

both objects. Data in which mice spent less than 10 seconds total exploring both objects in either the sample or test trial were excluded.

2.2.2. Pattern separation test (PST)

This test also involved three sequential trials, with a few key changes (Figure 1B, top panel). First, the mouse spent five minutes exploring an empty open field that had a graphic black and white pattern (P1) on the floor of the field and two identical objects. Next, the mouse spent five minutes exploring an empty open field that had a different graphic black and white pattern (P2) on the floor of the field and two different identical objects. Following an inter-trial interval of 3 hours, the mouse spent five minutes in a test trial, in which the P2 pattern was on the floor with one object from the P2 phase (familiar) and one object from the P1 phase (novel). The behavior of the mice was video-tracked as described for the OLT, with data collected on the time exploring the novel and familiar objects, distance traveled, and velocity of movement. Percent time spent with the novel object in P2 was calculated as total time exploring the novel object divided by total time exploring both objects. Data in which mice spent less than 10 seconds total exploring both objects in any trial were excluded.

2.2.3. Novel object recognition test (NORT)

This test involved three sequential trials (Figure 1C, top panel): an initial habituation trial as described for the OLT, a second sample trial in which the mouse explored the open field containing two identical objects, and, following an inter-trial interval of 2 hours (5 months post-exposure) or 5 hours (12 months post-exposure), a test trial in which one of the original objects was replaced with a novel object placed in the same location The behavior of the mice was video-tracked as

described for the OLT, with data collected on the time exploring the novel and familiar objects,

distance traveled, and velocity of movement. Percent time spent with the novel object was

calculated as total time exploring the novel object divided by total time exploring both objects.

Data in which mice spent less than 10 seconds total exploring both objects in either the sample or

test trial were excluded.

2.2.4. Elevated plus maze (EPMT)

The EPMT uses a grey colored maze consisting of a 60 cm elevated plus-shaped apparatus with

four arms, each 35 cm in length and 5 cm in width. Two of the arms are surrounded with walls on

three sides of 15 cm in height ("closed arms") and two of the arms are open ("open arms")

(Supplemental Figure 2A). Mice were gently placed in the center of the platform, facing a closed

arm, and allowed to freely explore the maze for one five minute interval. The movement of the

mouse in the sample and test trials were continuously video-tracked using the Noldus Ethovision

XT program, with data collected on: the time that the mouse center-point was observed in open

arms, closed arms, and the center of the maze; number of visits to open arms, closed arms, and the

center of the maze; distance traveled; and velocity of movement.

2.3. Immunohistochemical methods

Twelve months after exposure to GWIC, mice were perfused with 4% paraformaldehyde. Brains

were postfixed for 18 hours in 4% paraformaldehyde and cryoprotected in 30% sucrose. A cryostat

was then used to cut thirty-micrometer thick coronal sections through the entire brain. The sections

were collected serially in 24-well plates containing phosphate buffer; sections through the cerebral

cortex at hippocampal levels were chosen and processed for immunohistochemical quantification

of glial fibrillary acidic protein (GFAP)-positive astrocytes and ionized calcium-binding adaptor

molecular 1 (IBA-1)-positive microglia. Briefly, sections were incubated in 20% methanol and 3%

hydrogen peroxide in phosphate buffered saline (PBS) for 20 minutes, rinsed three times in PBS,

then incubated for 30 minutes in PBS containing 0.1% Triton-X 100 and 10% serum (Sigma).

Following this, sections were incubated in primary antibody (rabbit anti-GFAP antibody or goat

anti-IBA-1 antibody, both from Abcam) for 18-48 hours, then biotinylated secondary antibody

(biotinylated horse anti-goat IgG or biotinylated goat anti-rabbit IgG from Vector Laboratories)

for 60 minutes, then an avidin/biotin complex reagent (Vectastain Elite ABC HRP Kit) for 60

minutes, with a triple wash in PBS between each incubation step. The peroxidase reaction was

developed using Vector SG HRP substrate (Vector Laboratories), then sections were mounted on

gelatin-coated slides, dehydrated, cleared, and coverslipped.

2.4. Analysis of hippocampal inflammation

Astrocyte hypertrophy was evaluated using ImageJ to calculate area fraction of GFAP+ structures

in three regions (CA1, CA3, and dentate gyrus) of the hippocampus in six mice per genotype per

sex, for DMSO- and GWIC-exposed cohorts. Multiple sections were imaged per mouse and

averaged; image collection and ImageJ analysis were blinded to treatment group. Microglia

activation was evaluated by performing morphological analysis. Microglia were identified as IBA-

1 structures, while activated microglia were identified as IBA-1+ structures with swollen, ramified

cell bodies and short, thick processes[26]. Total microglia and activated microglia were counted for

three regions (CA1, CA3, and dentate gyrus, DG) of the hippocampus. Percentages of activated

microglia among total microglia were computed and compared. Multiple sections were imaged per

mouse and averaged; image collection and morphologic analysis was blinded to treatment group.

2.5 Tissue processing and expression analysis

For collection of tissues, animals were sacrificed and brains were quickly removed. The entire

hippocampus from both hemispheres and cerebral cortex tissues were micro-dissected from each

brain, then snap frozen on dry ice. Cells and tissues were lysed in 1% NP-40 lysis buffer

supplemented with protease inhibitor and then centrifuged at 12,000 x g, 4 °C to obtain cellular

lysate. After BCA protein assay (Thermo Fisher Scientific), equal amounts of protein (10–20 µg)

were separated on 10-20% SDS–PAGE gradient gels, then transferred onto PVDF membranes.

After air drying to return to a hydrophobic state, membranes were incubated in primary antibodies

(Table 1) at 4°C overnight in 1X PBS containing 1% casein and 0.02% sodium azide. After

incubating with HRP-conjugated secondary antibody at room temperature for 1 hour, membranes

were developed with Luminata Crescendo Western HRP Substrate (Millipore). Densitometry was

performed in ImageJ and normalized to the GAPDH expression level.

2.6 In vitro bone marrow-derived macrophage experiments

L929 cells were obtained from ATCC and maintained in DMEM (D5796) (Sigma) supplemented

with 10% FBS (97068-085) (VWR). Bone marrow-derived macrophages (BMDMs) were

generated from bone marrow collected from femurs and tibiae isolated from male and female mice.

Briefly, legs were dissected from mice and muscle and tissue were removed. Bones were immersed

in 70% EtOH then washed with PBS. Bones were crushed with a mortar and pestle and the marrow

was collected in DMEM. The marrow was passed through a 70 µm mesh strainer, then blood cells

were lysed using ACK lysis buffer. Remaining cells were passed through a 40 µm mesh strainer

and plated on Petri dishes in DMEM containing 10% FBS and 30% L929 culture media for 7 days.

For all experiments, BMDMs were plated at a density of 6 x 10^5 cells/mL unless otherwise

indicated. After cells were plated and allowed to adhere for 2-3 hours, cells in GWIC treatment

group were treated overnight with permethrin (10 μM final) and/or pyridostigmine bromide (PB,

100 ng/mL) as indicated. LPS treatment was done with LPS-B5 Ultrapure (InvivoGen) at a

concentration of 200 ng/mL unless otherwise indicated. Transfection of HSV-60bp interferon-

stimulatory DNA (ISD) (InvivoGen) into the cytosol of BMDMs was performed using

Polyethyleneimine (PEI) (43896) (Alfa Aesar).

2.7 ELISA

Primary, secondary, and detection antibodies were purchased from BioLegend. Detached cells and

debris were removed from cell culture supernatant by centrifugation prior to the assay. After

incubating half-well ELISA plates in capture antibodies at 4°C overnight, plates were blocked with

PBS containing 10% FBS at room temperature for 1 hour. Cell culture supernatants were diluted

80-240x (for IL-6) or 2-20x (for TNF-α) in blocking buffer. Standards and cell culture supernatant

were added to the ELISA plates and incubated at room temperature for 2 hours. Plates were

incubated at room temperature with biotin-conjugated secondary antibody for 1 hour, followed by

Avidin-HPR and detection with a TMB Substrate Set (BioLegend). Plates were washed 4 times

with PBS containing 0.05% Tween-20 between each step.

2.8 Metabolic analysis

The Seahorse XFe96 Analyzer was used to measure mitochondrial respiration and glycolysis

simultaneously following a modified protocol. Briefly, BMDMs were plated at a density of $6x10^4$

cells/well in 80μL of culture medium in an Agilent Seahorse XF96 Cell Culture Microplate. After

3 hours, an additional 80 µL of medium was added containing permethrin (10 µM final) and/or

pyridostigmine bromide (100 ng/mL final) as indicated. After incubating overnight, an additional

40 µL culture medium containing LPS (200 ng/µL final) was added as indicated. Following a 6 hr

incubation, cells were washed and media was replaced with XF assay medium (Base Medium

Minimal DMEM lacking glucose, glutamine, and bicarbonate, supplemented with 2 mM Ala-Gln,

pH 7.4) prior to analysis. Oxygen consumption rate (OCR) and extracellular acidification rate

(ECAR) were measured after sequential addition of glucose 25 mM; oligomycin (1.5 uM); FCCP

(1.5 µM) + sodium pyruvate (1mM) and; antimycin A (833 nM) + rotenone (833 nM). Beginning

the run with glucose omitted from the medium allows both respirator and glycolytic parameters to

be determined in the same run. Respiratory and glycolytic parameters were calculated using the

equations outlined in the Seahorse XF Mito Stress Test and Glycolysis Stress Test manuals.

2.9 Statistical analyses

All p-values were calculated using two-tailed, unpaired, Student's t-test, one-way ANOVA with

Tukey's multiple comparison, or the two-stage step-up method to yield q values that have been

corrected for the false discovery rate in Excel or GraphPad Prism as indicated in figure legends.

3. Results

3.1. Female GWIC-exposed mice display more pronounced impairments in cognitive

function and mood than male GWIC-exposed mice.

To establish GWIC-dependent cognitive symptoms in our model, we employed a battery of tests

to characterize neurobehavioral changes following GWIC exposure. A randomly selected subset

of GWIC- and DMSO-treated male and female C57BL/6 wild-type (WT) mice were tested for the

hippocampal-dependent ability to perceive changes in the environment using an object location

test (OLT)[27]. Notably, at both 5 months and 12 months post-exposure, female GWIC-exposed mice

showed impairment, failing to show a statistically significant affinity for the object in a novel

location during the testing phase (Figure 1A). Male GWIC-exposed mice did not display this

impairment, nor did DMSO-exposed mice, regardless of sex. The same cohorts were tested for

pattern separation ability using the pattern separation test (PST), which relies on the integrity of

the dentate gyrus of the hippocampus[27]. As observed in the OLT, female GWIC-exposed mice

showed impairment in the testing phase, while male GWIC-exposed mice and DMSO-exposed

mice of both sexes showed a statistically significant increase in affinity for the novel object in

pattern 2, reflecting pattern separation ability (Figure 1B). For both tests, control data for total

exploration time, total distance moved, and velocity of movement in the testing phase were similar

between testing groups (Supplemental Figure 1), indicating that variable object exploration or

motor deficits do not explain the differences in test performance. Rather, these results indicate an

impairment in hippocampal function in female, but not male, GWIC-exposed mice at 5 and 12

months post-exposure.

We observed similar sex-differences in tests of mood function following GWIC-exposure.

At 5 months post-exposure, we used the elevated plus maze test (EPMT) (Supplemental Figure

2A) to determine unconditioned response to a potentially dangerous environment and anxiety-

related behavior[28,29]. We observed a trend in which female, not male, GWIC-exposed mice spent

less time in open maze arms (Supplemental Figure 2B) and more time in closed maze arms or the

center (Supplemental Figure 2D), consistent with anxiety-related behaviors. Calculation of the

ratio of visits to the closed arms or center region of the maze versus visits to the open arms revealed

a statistically significant increase in preference for the closed arms or center of the maze in GWIC-

exposed female mice, but not GWIC-exposed male mice, as compared to DMSO-exposed

counterparts (Supplemental Figure 2C). As with the OLT and PST, control data were similar

among all cohorts (Supplemental Figure 2E), ruling out motor deficits as the underlying reason for

differences in EPMT performance. These results suggest that an increase in anxiety-related

behavior is an additional sex-dependent neurobehavioral change following GWIC-exposure.

3.2. Female and male GWIC-exposed mice display similarly impaired object recognition

memory.

Cohorts of mice also were tested for object recognition memory using the novel object recognition

test (NORT). Both male and female GWIC-exposed mice failed to show an affinity for the novel

object during the testing phase of the NORT, indicating impaired recognition memory. DMSO-

exposed mice, regardless of sex, spent a significantly greater amount of object exploration time

with the novel object during the testing phase (Figure 1C). As with the OLT and PST tests, control

data were comparable among treatment groups (Supplemental Figure 1), indicating that variable

object exploration or motor deficits do not explain the differences in test performance.

While both male and female GWIC-exposed mice display impairment on the NORT, which

depends primarily upon the integrity of the perirhinal cortex region of the cerebral cortex and

partially the hippocampus[27], only female GWIC-exposed mice display impairment on two tests

(OLT, PST) that rely on hippocampal function. This suggests that female GWIC-exposed mice

may exhibit increased hippocampal pathology, which may include mitochondrial alterations and

neuroinflammation, compared to GWIC-exposed male mice.

3.3. GWIC-exposed mice display sex-dependent alterations in expression of mitochondrial

proteins in the hippocampus and cerebral cortex.

To evaluate mitochondrial changes in the brains of these male and female GWIC-exposed mice,

we performed comparative expression analysis of regions required for performance of these

neurocognitive tests: the hippocampus, required for the OLT, NORT, and PST, and the cerebral

cortex, required for the NORT. Following completion of behavioral tests at 12 months, brains were

microdissected to isolate the hippocampus and cerebral cortex (CC), and protein extracts generated

were subjected to Western blotting and densitometry quantification.

Examination of an array of mitochondrial proteins revealed widespread rewiring of

mitochondrial protein expression, particularly enzymes involved in oxidative phosphorylation

complexes I-V (OXPHOS CI-CV). Interestingly, the directionality of the expression changes

varied between male and female mice, with the expression of several OXPHOS proteins

(NDUFB8, UQCRC2, and MT-COI) significantly increasing in the hippocampi of GWIC-exposed

female mice (Figure 2A) but trending towards a decrease in the hippocampi of GWIC-exposed

male mice (Figure 2B). Similarly, moderate reductions in abundance of MnSOD (mitochondrial

superoxide dismutase that generates hydrogen peroxide), OGDH (TCA cycle enzyme), and TFAM

(mtDNA packaging protein) were observed in female, but not male, GWIC-exposed hippocampi.

Notably, this observation of more pronounced changes in mitochondrial expression within the

hippocampus of female GWIC-exposed mice parallels our earlier finding that GWIC-exposed

female mice show greater impairment in hippocampal-dependent neurocognitive tests.

Analysis of extracts from the CC also reveals sex-dependent directionality of expression

changes. Although expression of UQCRC2 was largely unchanged in the hippocampi of GWIC-

exposed male mice, it is significantly decreased in CC extracts from these animals (Figure 2D). In

contrast, UQCRC2 levels in CC extracts isolated from female GWIC-exposed mice show a modest

increase (Figure 2C), echoing the varied directionality observed in the hippocampus. Similarly,

we observed a trending decrease in expression of MT-COI, ATP5A, and SDHA in CC extracts of

male, but not female, mice. Overall, these changes in mitochondrial protein abundance reveal sex-

dependent OXPHOS remodeling, which persists for 12 months after exposure to GWIC and tracks

with neurocognitive impairments.

3.4. Female GWIC-exposed mice exhibit increased neuroinflammation as compared to male

GWIC-exposed mice.

To assess neuroinflammation after GWIC exposure, perfused brains from female and male mice

were fixed, sectioned, and processed for immunohistochemical quantification of glial fibrillary

acidic protein (GFAP)-positive astrocytes and ionized calcium-binding adaptor molecular 1 (IBA-

1)-positive microglia. Quantification of astrocytes in the dentate gyrus (DG), CA1, and CA3

regions of the hippocampus (Figure 3) revealed that female GWIC-exposed mice displayed

significantly increased GFAP+ structures in all three hippocampal regions as compared to female

DMSO-exposed mice. Male GWIC-exposed mice show significantly increased GFAP+ structures

in the DG region and CA3 region only. This observation, which indicates more widespread

hippocampal inflammation in female GWIC-exposed mice as compared to male GWIC-exposed

mice, is consistent with our findings that female GWIC-exposed mice display increased

impairment on hippocampal-dependent neurobehavioral tests.

A study by Zakirova and colleagues of neuroinflammation in this murine model of GWIC-

exposure have likewise observed significant increases of astrocyte hypertrophy in the dentate

gyrus of the hippocampus, as measured by GFAP quantification. Notably, this study, which

exclusively used male mice, did not observe a significant increase in activated IBA-1+ microglia

following GWIC-exposure[24]. In contrast, when we performed blinded morphological scoring of

IBA-1+ cells with the DG, CA1, and CA3 of hippocampi from GWIC- and DMSO-exposed male

and female mice, we observed a significant increase in activated microglia within the DG of

female, but not male, GWIC-exposed mice as compared to DMSO-exposed mice (Supplemental

Figure 7A). Significant increases were not observed in the CA1 or CA3 hippocampal regions of

female or male GWIC-exposed mice, and male GWIC-exposed mice displayed a significant

reduction in IBA-1+ cells with an activated morphology within the CA1 region, consistent with

decreases in percent fraction of IBA-1+ cells observed by Zakirova *et al*. Our findings therefore

suggest a novel sex-dependent increase in activated microglia within the DG region of the

hippocampus in this model of GWIC-exposure.

3.5.   GWIC-exposure of cells results in metabolic alterations, enhanced expression of

interferon-stimulated genes, and increased production of inflammatory cytokines.

Our findings are consistent with the notion that GWIC exposure causes lasting mitochondrial

rewiring and neuroinflammation. However, a direct effect of GWIC on metabolism and/or innate

immune signaling has not been documented. Therefore, to characterize the immediate impact of

GWIC on mitochondrial function and cell-intrinsic innate immune responses, we performed a

series of acute, in vitro experiments using bone marrow-derived macrophages (BMDMs). While

not derived from the brain, BMDMs provide a robust cellular platform to evaluate mitochondrial

function, innate immune responses, and the dynamic interplay between these pathways[30]. To first

evaluate GWIC-dependent changes in oxygen consumption and glycolysis, BMDMs were treated

overnight with permethrin (Per) alone, pyridostigmine bromide (PB) alone, or, as in *in vivo*

experiments, both of these GWIC (Per-PB), then subjected to analysis of mitochondrial respiration

using a Seahorse XF96 Analyzer. Per or Per-PB exposed BMDMs exhibited significantly

increased basal mitochondrial oxygen consumption (OCR), with unchanged maximal respiration

(Figure 4A), while treatment with PB only failed to increase basal respiration and resulted in

significantly diminished maximal respiration. Treatment with Per, PB, or Per-PB decreased spare

respiratory capacity, accompanied by an increase in proton leak for Per- and Per-PB-treated

BMDMs. Overall, these data indicate that acute exposure to GWIC induces changes to

mitochondrial OXPHOS and are consistent with the in vivo findings described in Section 3.3.

Additional changes were observed when BMDMs were treated with bacterial lipopolysaccharide

(LPS, an agonist of the innate immune sensor Toll-like receptor 4 (TLR4)) in combination with

GWIC. Per or Per-PB pretreatment followed by LPS resulted in an increase in basal respiration,

as seen in mock-treated cells, as well as a significant increase in maximal respiration (Figure 4B).

Interestingly, LPS treatment resulted in significantly increased spare respiratory capacity upon

exposure to all three GWIC combinations, though this could be due to the increase in maximal

respiration. Following LPS treatment, proton leak was increased only in Per cells. Additional

studies analyzing a surrogate marker of glycolysis, the extracellular acidification rate (ECAR),

revealed that while glycolysis was largely unchanged following GWIC-exposure alone

(Supplemental Figure 3B), treatment with GWIC plus LPS resulted in cells becoming more

glycolytic (Supplemental Figure 3C), consistent with the immunometabolic changes typically seen

in inflammatory M1 macrophages.

Prior work has shown that systemic LPS-induced TLR4 activation contributes to GWIC-

related neuroinflammation[31]. To examine the direct effects of GWIC exposure on innate immune

signaling, we first measured expression of induced proteins following LPS-stimulation of BMDMs

that had been pre-treated with Per, PB, or Per-PB. We observed modest increases in expression of

the interferon regulatory factor IRF1 in BMDMs exposed to LPS plus Per and/or Per-PB, as well

as modestly elevated levels of the interferon stimulated gene (ISG) IFIT3 after 6 hours of LPS plus

PB and Per-PB exposure (Supplemental Figure 3A). Additional work in BMDMs revealed synergy

between the STING innate immune pathway, as transfection of interferon stimulatory DNA (ISD)

to activate STING after pretreatment with GWIC resulted in modestly elevated ISG expression

(Figure 4C). Moreover, we noted an increase in pro-IL-1β cytokine abundance after LPS plus

GWIC (Figure 4D). In fact, PB increased Caspase I cleavage to the active p20 isoform in both

untreated and LPS-treated cells, a process that requires activation of cytosolic inflammasomes

such as NLRP3. Finally, ELISA analysis of BMDMs revealed that GWIC exposure synergized

with LPS stimulation and resulted in increased proinflammatory cytokine production: Per or Per-

PB treatment led to increased production of both IL-6 and TNF-α after 24 hours of LPS treatment

(Figure 4E). Interestingly, though PB alone inhibited IL-6 and TNF-α production, it acted

synergistically with Per and enhanced IL-6 and TNF-α production over Per treatment alone.

Overall, our results reveal that GWIC induce immunometabolic rewiring of OXPHOS and

glycolysis in BMDMs and potentiate inflammatory responses to innate immune stimulation.

3.6.   **Ablation of STING or NLRP3 signaling improves neurocognitive deficits and**

neuroinflammation and blunts changes in mitochondrial protein expression following

GWIC-exposure.

Our in vivo experiments using a mouse model of GWI have demonstrated neurocognitive deficits,

changes in expression of mitochondrial proteins, and hippocampal inflammation caused by GWIC,

with more severe symptoms observed in female mice. Our *in vitro* experiments using BMDMs

revealed metabolic changes and heightened innate immune responses following GWIC treatment,

including increased production of ISGs and the proinflammatory cytokines IL-1β, IL-6, and TNFα.

Notably, BMDM experiments suggested potentiated TLR4, STING, and NLRP3 innate immune

signaling in response to acute GWIC exposure.

Stress, infection, or injury can cause MD, which leads to the release of mitochondrial

constituents such as mtDNA, mitochondrial lipids (cardiolipin), *N*-formyl peptides, mitochondrial

metabolites (succinate), and high concentrations of ATP[21]. These so-called damage-associated

molecular patterns (DAMPs) then trigger the innate immune system via several paths. mtDNA can

be detected by the enzyme cGAS, which then generates the cyclic dinucleotide cGAMP, a second

messenger that binds and activates STING[32] for expression of type I interferons and ISGs[33].

Likewise, over-production of ROS, mtDAMP release, and altered mitochondrial dynamics due to

MD engage the NLRP3 inflammasome, triggering processing of pro-interleukin-1 beta (pro-IL-

1β) into IL-1β[34,35]. Both STING and NLRP3 are therefore key mechanisms by which MD and

mtDAMPs can engage the innate immune system, and the increases in ISGs and IL-1β observed

in Figure 4C, Figure 4D, and Supplemental Figure 3A implicate both pathways downstream of

GWIC.

To interrogate the contribution of STING and NLRP3 signaling to neurobehavioral

changes, neuroinflammation, and mitochondrial rewiring following GWIC exposure, cohorts of

STING[gt/gt] and NLRP3[-/-] mice on a C57BL/6 background were exposed to DMSO or GWIC in

parallel to wild-type C57BL/6 (WT) mice. STING[gt/gt] mice are homozygous for an I199N missense

mutant allele in the *Sting* gene and express no STING protein[36], while NLRP3[-/-] mice are

homozygous for a neo cassette in the coding region of *Nlrp3* and are therefore deficient in the

NLRP3 inflammasome[37].

Neurobehavioral tests of STING[gt/gt] mice revealed that observed impairments of GWIC-

exposed mice are STING-dependent. In contrast to WT GWIC-exposed cohorts, GWIC-treated

STING[gt/gt] female mice demonstrated rescue of object location memory by successfully

completing the OLT at both 5 months post-exposure (Figure 5A) and at 12 months post-exposure

(Supplemental Figure 4A). Similarly, GWIC-treated STING[gt/gt] female mice at 5 months post-

exposure (Figure 5A) and GWIC-treated STING[gt/gt] male mice at 12 months post-exposure

(Supplemental Figure 4B) were unimpaired in the NORT. These findings suggest that STING

signaling may contribute to impairment of both hippocampal function in female mice and cerebral

cortex function in male and female mice following GWIC exposure.

Interestingly, neurobehavioral tests of NLRP3[-/-] mice suggest that neurobehavioral changes

due to GWIC exposure are only partially NLRP3-dependent. Like GWIC-treated female WT mice,

female NLRP3[-/-] mice display impaired object location recognition at 5 months (Figure 6A) and

12 months (Supplemental Figure 4A) post-exposure, indicating that NLRP3 signaling is not

important for the development of this neurocognitive change. Additionally, although female

NLRP3[-/-] mice at 5 months post-exposure show restored novel object recognition (Figure 6A), this

restoration was lost at 12 months post-exposure (Supplemental Figure 4B).

Ablation of STING signaling and the NLRP3 inflammasome appears to improve mood

function in female mice following GWIC-exposure. While WT GWIC-exposed female mice

displayed a statistically significant preference for the closed arms or center of the maze during the

EPMT, STING[gt/gt] and NLRP3[-/-] female mice fail to show this preference (Supplemental Figure

4D). STING$^{gt/gt}$ and NLRP3$^{-/-}$ GWIC-exposed male mice behave similarly to WT counterparts,

without an observed preference (Supplemental Figure 4D).

The results of the experiments described above demonstrate that STING and NLRP3

contribute to GWI-dependent neurocognitive changes to a varying degree. Additional

neurobehavioral tests were more difficult to interpret at the inter-trial intervals employed in the

study. For example, both DMSO- and GWIC-treated STING$^{gt/gt}$ female mice are deficient in novel

object recognition at 12 months post-exposure, indicating non-treatment specific, aging-related

neurobehavioral changes in these mice (Supplemental Figure 4B). Similarly, STING$^{gt/gt}$ and

NLRP3$^{-/-}$ female and male mice showed impaired pattern separation ability, regardless of

treatment, at 5 months post-exposure (Supplemental Figure 4C). Because of this, we cannot draw

conclusions from 12 month post-exposure NORT tests in female mice or 5 month post-exposure

PST tests in female or male mice. While STING signaling or the NLRP3 inflammasome may in

fact impact neurobehavioral changes as measured by these assays, changes to the DMSO-treatment

control mice make conclusions impossible.

Other tests were also inconclusive. The validity of NORT testing of GWIC-treated

STING$^{gt/gt}$ male mice at 5 months and NLRP3$^{-/-}$ male mice at 5 and 12 months is uncertain due to

the failure of DMSO-treated control cohorts to spend significantly increased time with the novel

object (Supplemental Figure 4B). In the case of the DMSO-treated STING$^{gt/gt}$ mice at 5 months

post-exposure, controls measurements indicated decreased movement and object exploration

(Supplemental Figure 5). However, for all other groups and tests, control data indicate that variable

object exploration or motor deficits do not explain test performance (Supplemental Figure 5).

In the WT GWIC-exposed female mice, deficiencies in neurobehavioral tests correlated

with increased astrocyte hypertrophy in three regions of the hippocampus. In contrast, both

STING$^{gt/gt}$ and NLRP3$^{-/-}$ female mice failed to show increased astrocyte hypertrophy in the DG

(Figure 5B, Figure 6B) or the CA1 and CA3 regions (Supplemental Figure 6A, 6B) as compared

to DMSO-treated WT controls. Expression of GFAP in the hippocampi of DMSO-treated WT,

STING$^{gt/gt}$, and NLRP3$^{-/-}$ were comparable (Supplemental Figure 6C), suggesting that this

observation is due to lessened GWIC-induced neuroinflammation in the absence of STING or

NLRP3. In addition, analysis of IBA-1+ cells within the hippocampus also revealed a decrease in

activated microglia within the DG of STING$^{gt/gt}$, and NLRP3$^{-/-}$ GWIC-exposed female mice

(Supplemental Figure 7A, 7B) as compared to WT GWIC-exposed female mice.

STING and NLRP3 therefore play a role in driving neurocognitive changes and

neuroinflammation following GWIC exposure. To assess the impact on mitochondrial expression

changes, extracts of the hippocampi (Figure 5C and 5E, Figure 6C and 6E) and cerebral cortices

(Figure 5D and 5F, Figure 6D and 6F) of DMSO- and GWIC-exposed STING$^{gt/gt}$ and NLRP3$^{-/-}$

mice were analyzed as in Figure 2. Hippocampal extracts from both STING$^{gt/gt}$ (Figure 5C) and

NLRP3$^{-/-}$ female mice (Figure 6C) no longer show the significant increase in NDUFB8 observed

in WT female mice, and STING$^{gt/gt}$ female mice also show a downward trend in UQCRC2

expression and a significant decrease in MT-COI, in contrast to the significant upregulation of

both in WT female mice. We also observed an upward trend of expression for UQCRC2, MT-COI,

ATP5A, and SDHA in the CC of STING$^{gt/gt}$ males (Figure 5F), which were all downregulated in

WT males. Overall, expression analysis of STING$^{gt/gt}$ and NLRP3$^{-/-}$ brains echoes other findings

with these mice: the absence of these signaling hubs reduces cognitive impairment,

neuroinflammation, and mitochondrial expression changes, with findings indicating a more

significant role for STING than for NLRP3.

4. Discussion

Using an established murine model of GWI[22,29,24], we demonstrated that GWIC-exposed female

mice display impaired object location memory and novel object recognition at 5 and 12 months

post-exposure, and impaired pattern separation at 5 months post-exposure. These results show that

female mice have more severe GWIC-dependent neurocognitive impairment than males, which in

our studies showed impairment only in novel object recognition and no anxiety-related behavior

as measured by the EPMT. A previous study examining both female and male C57BL/6 mice also

demonstrated increased anxiety in female mice, as measured by the open field test (OFT)[38].

However, the majority of GWI rodent model studies have used male mice only, using tests

including the Barnes maze[24,29,7,39] , forced swim test[39,40], and OFT[38,35,26] to reveal cognitive

impairment, fatigue, and anxiety-related behavior. We tested both female and male GWIC-

exposed mice using the OLT, NORT, and PST, which has been used in GWI rat models to show

impairment in male animals with demonstrated hippocampal inflammation[27,42,43,44]. We also used

the EPMT, which has shown disinhibition type behaviors in GWIC-exposed male mice[29] that we

did not observe, likely due to differences in time post-exposure. This study is therefore the first

time female GWIC-exposed mice have been evaluated for neurocognitive impairment using this

battery of tests. While women represented a relatively small percentage (7%) of the active duty

population during PGW-1[45], chronic GWI conditions differ in female and male PGW-1 veterans[46],

with some studies showing female veterans PGW-1 as more likely to meet the clinical criteria of

GWI and to display heightened, longer-lasting GWI symptoms than male veterans[47,48]. Therefore,

there is a critical need to better understand sex differences in GWI pathology. The more significant

neurocognitive impairment that we observed in female mice makes a strong argument for inclusion

of both sexes in future pre-clinical GWI studies involving rodents.

In addition to cognitive impairment, we observed astrocyte hypertrophy within all three

examined regions (dentate gyrus, CA1, and CA3) of the hippocampi of GWIC-exposed female

mice, as compared to only two regions (DG and CA3) in male mice. Comparison of DMSO-

exposed female and male mice revealed that control males appear to have heightened astrocyte

hypertrophy as compared to control females, which may explain the diminished GWIC-dependent

increase. We also observed an increase in IBA-1+ microglia with an activated morphology in the

dentate gyri of GWIC-exposed female mice, with a decrease observed in GWIC-exposed male

mice, consistent with a previous study[29]. Overall, this novel observation of more severe

hippocampal inflammation observed in GWIC-exposed female mice further emphasizes the value

of using both male and female mice for future GWI study.

Our analysis of expression of mitochondrial proteins in the hippocampi of GWIC-exposed

mice adds to the growing body of evidence that MD is an important factor in the pathology of

GWI. MD[49] and mtDNA lesions[50] have been documented in GWI patients, and animal studies

analyzing expression of nuclear and mitochondrially encoded OXPHOS proteins from whole brain

extracts have demonstrated widespread expression changes in mice[51] and rats[3]. We observed

decreases in OXPHOS proteins in male mice exposed to GWICs in both the hippocampus and

peripheral cortex. In contrast, OXPHOS protein expression in female mice increased in response

to GWICs, particularly in the hippocampus, while other mitochondrial proteins including SDHB,

MnSOD, TFAM, and OGDH show a modest decrease in expression. This suggests a general

rewiring of mitochondrial protein expression, rather than a wholesale decrease in all mitochondrial

proteins, that is most severe in hippocampi of female mice.

In vitro studies centered around acute treatment of BMDMs provided further evidence of

disruptions to mitochondrial metabolism. Of the two GWIC, permethrin was the main driver for

alterations to mitochondrial respiration, leading to an increase in basal respiration, loss of spare

respiratory capacity, and increase in proton leak. Though PB alone had little effect, it appeared to

act synergistically with Per, causing further alterations to basal respiration and spare respiratory

capacity in control cells and an increase in spare respiratory capacity in LPS-treated cells. We

observed a similar synergistic interaction when we analyzed production of IL-6 and TNFα after

LPS stimulation. Per alone induced an increase in cytokine release, while PB alone had little effect;

however, treatment with Per and PB together induced an even stronger response. A likely

explanation for this observation is that Per and PB are acting through separate but complimentary

pathways. BMDMs treated with Per showed increased expression of ISGs than either untreated or

PB treated cells after induction with LPS or ISD. Alternatively, BMDMs treated with PB displayed

increased expression of pro-IL-1β and increased cleavage of Caspase I. Thought the effect was

subtle, this suggests low levels of activation of the NLRP3 inflammasome in response to PB.

Consistent with this notion, elevated serum levels of IL-1β and IL-6 have been observed in patients

with GWI, and elevated IL-1β, IL-6, and TNFα have been observed in the brains of mice exposed

to GWICs[3,43,52–54].

As in other studies, our analysis of C57BL/6 WT GWIC-exposed mice and of GWIC-

treated BMDMs demonstrated contemporaneous MD and inflammation. GWIC-exposure

experiments with STING[gt/gt] and NLRP3[-/-] mice suggest a link between the two. Loss of STING in

female mice restores hippocampal-dependent object location memory at both 5 and 12 months

post GWIC exposure and novel object recognition ability at 5 months post-exposure; loss of

STING also restores novel object recognition in male GWIC-exposed mice. These data strongly

suggest a role for STING in driving neurocognitive changes following GWIC-exposure. Loss of

NLRP3 has a subtler effect, restoring novel object recognition in female GWIC-exposed mice at

5 months, but not 12 months, post-exposure. This may indicate a role for NLRP3 in relatively

short-term impairment in novel object recognition following GWIC-exposure. These findings are

limited by the behavioral tests we employed and by the validity of these tests. As described in

Section 3.6, several of the tests of STING$^{gt/gt}$ and NLRP3$^{-/-}$ mice were inconclusive due to

impairment observed in control animals or by the failure of cohorts to spend sufficient time in

object exploration. However, we were able to draw conclusions from several OLT, NORT, and

EPMT tests, which on their own suggest a significant role for STING and a potentially lesser,

time-dependent role for NLRP3 in driving neurocognitive impairment.

Analysis of neuroinflammation and expression of mitochondrial proteins within the

hippocampi and cerebral cortices of GWIC-exposed mice also support a role for STING and

NLRP3 in GWI. Loss of STING or NLRP3 in female mice results in a significant diminishment

of astrocyte hypertrophy in all three regions of the hippocampus as compared to GWIC-exposed

WT females, as well as a significant decrease in microgliosis within the DG. The rewiring of

mitochondrial expression due to GWIC-exposure is also blunted or reversed in STING$^{gt/gt}$ and

NLRP3$^{-/-}$ mice. STING and NLRP3 therefore join TLR4[31] as innate immune sensors linked to

GWI-related pathology in murine models. Remaining questions include in which cell types and

tissues STING and/or NLRP3 signaling occurs to influence GWI symptoms, as well as the timing

of signaling following GWIC exposure. Future study using conditional transgenic models will

need to be conducted to address these questions. Comprehensive assessment of these innate

immune pathways in patient samples is also needed to confirm whether our findings extend to

veterans with GWI. If indeed these pathways are active, targeted intervention using STING and

NLRP3 inhibitors may be effective at alleviating some GWI symptoms and improving the

healthspan of this population.

Finally, therapeutic targeting of mitochondria to directly improve metabolic function is a

viable treatment strategy for GWI. Indeed, veterans with GWI have shown improvements in

symptoms in response to Coenzyme Q10 [55], an antioxidant and OXPHOS electron carrier known

to have beneficial effects on mitochondria, or KPAX002, a combination treatment designed to

boost mitochondrial function[56]. Emerging links between mitochondria and the innate immune

system raise the possibility that therapeutic approaches to improve mitochondrial health may also

serve to decrease inflammation, likely by reducing mtDAMP release/accumulation. Our work

implicates two of the main mtDAMP sensing pathways, STING and NLRP3, to GWIC-related

inflammation, mitochondrial/metabolic rewiring, and cognitive deficits. Therefore, an intriguing

future direction is to evaluate how different mitochondrial therapeutics affect neurocognitive

impairment, neuroinflammation, and mitochondrial protein expression within the brain of GWIC-

exposed mice to understand the efficacy, mechanisms, and perhaps sex-specific effects, of these

treatments.

Acknowledgements

We thank Sahithi Attaluri for assistance with immunohistochemical analysis and Dr. Alexandra

Trott, Associate Director of the TAMU Rodent Preclinical Phenotyping Core, for assistance with

behavioral tests. This work was supported, in part, by a grant from NIEHS P30 ESES029067 and

by awards W81XWH-17-1-0446 (to A.P.W.), W81XWH-16-1-0480 (to A.K.S.), and W81XWH-

17-1-0447 (to A.K.S.) from the Office of the Assistant Secretary of Defense for Health Affairs

through the Peer Reviewed Medical Research Programs, Gulf War Illness Research Program.

Opinions, interpretations, conclusions, and recommendations are those of the authors and are not

necessarily endorsed by the Department of Defense or the United States Government.

Competing interests statement

The authors declare no competing interests.

Figure 1. Exposure of C57BL/6 wild-type mice to GWIC results in sex-dependent impairment in spatial memory, pattern separation, and novel object reocognition.

Figure 1. Exposure of C57BL/6 wild-type mice to GWIC results in sex-dependent

impairments in spatial memory, pattern separation, and novel object recognition. (A) The

diagram in the top panel depicts the sequential phases used in the object location test (OLT): the

habituation phase, the sample phase, and the testing phase. Each phase lasted five minutes, and the

inter-trial interval (ITI) between the sample and testing phase was 20 minutes (5 months post-

exposure) or 2 hours (12 months post-exposure). The bar graphs in the bottom panel compare the

percentages of total exploration time spent with the object in the familiar location versus time spent

with the object in the novel location for both the OLT conducted 5 months and 12 months post-

exposure, for DMSO- and GWIC-exposed female and male mice. (B) The diagram in the top panel

depicts the sequential phases used in the pattern separation test (PST): the Pattern 1 phase, the

Pattern 2 phase, and the testing phase, in which one of the objects from Pattern 1 was placed into

Pattern 2. Each phase lasted five minutes, and the inter-trial interval (ITI) between the sample and

testing phase was 3 hours. The bar graphs in the bottom panel compare the percentages of total

exploration time spent with the familiar object in Pattern 2 versus time spent with the novel object

in Pattern 2 for a PST conducted 5 months post-exposure, for DMSO- and GWIC-exposed female

and male mice. (C) The diagram in the top panel depicts the sequential phases used in the novel

object recognition test (NORT): the habituation phase, the sample phase, and the testing phase.

Each phase lasted five minutes, and the inter-trial interval (ITI) between the sample and testing

phase was 2 hours (5 months post-exposure) or 6 hours (12 months post-exposure). The bar graphs

in the bottom panel compare the percentages of total exploration time spent with the familiar object

versus time spent with the novel object both the NORT conducted 5 months and 12 months post-

exposure, for DMSO- and GWIC-exposed female and male mice.). Error bars represent the mean

of biological replicates +/- SEM (n=9-10). Indicated p-values were calculated two-tailed, unpaired,

Student's t-test. $*p < 0.05$; $**p < 0.01$; $***p < 0.001$; $****p < 0.0001$; ns, not significant.

Figure 2. Exposure of C57BL/6 wild-type mice to GWIC results in sex-dependent alterations in expression of mitochondrial proteins in the hippocampus and cerebral cortex.

Figure 2. Exposure of C57BL/6 wild-type mice to GWIC results in sex-dependent alterations

in expression of mitochondrial proteins in the hippocampus and cerebral cortex. At 12

months post-exposure, tissue extracts were generated from microdissected hippocampi from

DMSO- and GWIC-exposed female mice (A) and male mice (B) and from cerebral cortex samples

from DMSO- or GWIC-exposed female mice (C) and male mice (D), and immunoblotted for the

listed proteins as described in Section 2.5 of materials and methods. Labels in parentheses next to

listed proteins designate proteins as part of complex I (CI), complex II (CII), complex III (CIII),

complex IV (CIV) or complex V (CV) of the electron transport chain. Densitometry for each

protein was performed in ImageJ and normalized to the GAPDH expression level. Bars represent

the $\log_2$ fold change (FC) of biological replicates +/- SD (n=3). Indicated p-values were calculated

using a two-tailed t test, and values below 0.05 are shown in bold.

Figure 3. Increased astrocyte hypertrophy is observed in three hippocampal regions of female GWIC-exposed mice and in two hippocampal regions of male GWIC-exposed mice.

Figure 3. Increased astrocyte hypertrophy is observed in three hippocampal regions of female GWIC-exposed mice and in two hippocampal regions of male GWIC-exposed mice. We measured percent fraction of glial-fibrillary acidic protein-expressing (GFAP+) cells within three regions of the hippocampus: the dentate gyrus (DG), CA1, and CA3. Images show representative distribution and morphology of GFAP+ astrocytes in these three regions in male and female GWIC-exposed and DMSO-exposed mice (scale bar = 100 µM). Insets show magnified views (scale bar = 50 µM); adjacent bar graphs show quantification of percent fraction GFAP+ for each cohort). Error bars represent the mean of biological replicates +/- SEM (n=6). Indicated p-values were calculated using two-tailed, unpaired, Student's t-test.. *p < 0.05; **p < 0.01; ns, not significant.

Figure 4. GWIC-exposure alters mitochondrial respiration and potentiates inflammatory responses in BMDMs.

Figure 4. GWIC exposure alters mitochondrial respiration and potentiate inflammatory

responses in BMDMs. (A) and (B) Oxygen consumption rate (OCR) in BMDMs treated with

GWIC. BMDMs were treated overnight with GWIC as indicated. Cells were treated with (A)

Seahorse medium (Mock) or (B) 200 ng/mL LPS (LPS) for 6 hours, then respiration was measured

on a Seahorse XF96 Analyzer using a modified protocol as described in Section 2.8 of materials

and methods. (C) ISG expression in BMDMs treated with GWIC and transfected with ISD.

BMDMs were treated overnight with GWIC as indicated, then transfected with 1 μg ISD for 6 or

24 hours. Cells extracts were blotted for indicated proteins as in Figure 2. (D) Inflammasome

activation in BMDMs treated with GWIC. BMDMs were treated overnight with GWIC as

indicated, then treated with 20 ng/mL LPS for 6 or 24 hours. Cells extracts were blotted for

indicated proteins as in Figure 2. (E) ELISA of inflammatory cytokines in BMDMs treated as in

(D). Data shown is representative of three separate experiments. Error bars represent the mean of

technical replicates +/- SD (n=5 for (A) and (B) and n=2 for (E)). Significance values for pairwise

comparisons were calculated using the two-stage step-up method to yield q values that have been

corrected for the false discovery rate. * $q < 0.05$; ** $q < 0.01$; *** $q < 0.001$; **** $q < 0.0001$.

Figure 5. Loss of STING attenuates GWIC-related neurobehavioral changes, neuroinflammation, and mitochondrial rewiring.

Figure 5. Loss of STING attenuates GWIC-related neurobehavioral changes,

neuroinflammation, and mitochondrial rewiring. (A) A comparison of OLT and NORT results

in DMSO- or GWIC-exposed WT and STING$^{gt/gt}$ C57BL/6 female mice. Error bars represent the

mean of biological replicates +/- SEM (OLT: n=3 for DMSO control mice, n=6 for GWIC-exposed

mice; NORT; n=4 for DMSO control mice, n=8 for GWIC-exposed mice). (B) Comparison of

percent fraction of GFAP+ cells within the dentate gyrus (DG), CA1, and CA3 of DMSO- or

GWIC-exposed WT female mice and GWIC-exposed STING$^{gt/gt}$ female mice. Indicated p-values

for (A) and (B) were calculated using two-tailed, unpaired, Student's t-test. *$p < 0.05$; **$p < 0.01$;

***$p < 0.001$; ****$p < 0.0001$; ns, not significant. (C) Hippocampal extracts from DMSO- and

GWIC-exposed female (C) and male (D) WT and STING$^{gt/gt}$ mice and cerebral cortex extracts

from DMSO- and GWIC-exposed female (E) and male (F) WT and STING$^{gt/gt}$ mice 12 months

post-exposure were generated and blotted as described in Figure 2. Green bars represent the log$_2$

fold change (FC) of biological replicates +/- SD (n=3) of STING$^{gt/gt}$ extracts, with each replicate

represented by a black dot. Blue bars in overlay represent the log$_2$ fold change (FC) of biological

replicates (n=3) of WT samples from Figure 2, for sake of comparison. Densitometry for each

protein was performed in ImageJ and normalized to the GAPDH expression level. Indicated p-

values, which refer to STING$^{gt/gt}$ samples, were calculated using a two-tailed t test, and values

below 0.05 are shown in bold.

Figure 6. Loss of NLRP3 attenuates GWIC-related neurobehavioral changes, neuroinflammation, and mitochondrial rewiring.

Figure 6. Loss of NLRP3 (partly) attenuates GWIC-related neurobehavioral changes,

neuroinflammation, and mitochondrial rewiring. (A) A comparison of OLT and NORT results

in DMSO- or GWIC-exposed WT and NLRP3$^{-/-}$ C57BL/6 female mice. Error bars represent the

mean of biological replicates +/- SEM (OLT: n=5 for DMSO control mice, n=10 for GWIC-

exposed mice; NORT; n=5 for DMSO control mice, n=9 for GWIC-exposed mice).   (B)

Comparison of percent fraction of GFAP+ cells within the dentate gyrus (DG), CA1, and CA3 of

DMSO- or GWIC-exposed WT female mice and GWIC-exposed NLRP3$^{-/-}$ female mice. Indicated

p-values for (A) and (B) were calculated using two-tailed, unpaired, Student's t-test. *p < 0.05;

**p < 0.01; ***p < 0.001; ****p < 0.0001. (C) Hippocampal extracts from DMSO- and GWIC-

exposed female (C) and male (D) WT and NLRP3$^{-/-}$ mice and cerebral cortex extracts from DMSO-

and GWIC-exposed female (E) and male (F) WT and NLRP3$^{-/-}$ mice 12 months post-exposure

were generated and blotted as described in Figure 2. Red bars represent the log$_2$ fold change (FC)

of biological replicates +/- SD (n=3) of NLRP3$^{-/-}$ extracts, with each replicate represented by black

dots. Blue bars in overlay represent the log$_2$ fold change (FC) of biological replicates (n=3) of WT

samples from Figure 2, for sake of comparison. Densitometry for each protein was performed in

ImageJ and normalized to the GAPDH expression level. Indicated p-values, which refer to NLRP3^{-}

$^{/-}$ samples, were calculated using a two-tailed t test, and values below 0.05 are shown in bold.

Supplemental Figure 1. Control data for OLT (object location test), PST (pattern separation test), and NORT (novel object recognition test) experiments depicted in Figure 1: total object exploration time, distance moved, and velocity.

Object Location Test
5 months

Object Location Test
12 months

Pattern Separation Test
5 months

Novel Object Recognition Test
5 months

Novel Object Recognition Test
12 months

Supplemental Figure 1. Control data for OLT (object location test), PST (pattern separation

test), and NORT (novel object recognition test) experiments depicted in Figure 1: total object

exploration time, distance moved, and velocity. For all the neurobehavioral tests (OLT, PST,

and NORT) depicted in Figure 1, data were collected on total object exploration time (seconds),

distance moved (meters), and velocity (centimeters per second) of all mice for all three tests (object

location test, OLT; pattern separation test, PST; novel object recognition test, NORT). Error bars

represent the mean of biological replicates +/- SEM (n=9-10). Indicated p-values were calculated

using one-way ANOVA with Tukey's multiple comparison. *p < 0.05; **p < 0.01; ns, not

significant.

Supplemental Figure 2. The elevated plus maze test (EPMT) was used at 5 months post exposure to assess anxiety-related behavior in all cohorts.

Supplemental Figure 2. The elevated plus maze test (EPMT) was used at 5 months post-exposure to assess anxiety-related behavior in all cohorts. (A) The diagram depicts the experimental setup for this test: a 60 cm elevated plus-shaped apparatus with four arms, each 35 cm in length and 5 cm in width. Two of the arms are surrounded with walls on three sides of 15 cm in height (the two regions identified as "closed arm" in the diagram) and two of the arms are open (the two regions identified as "open arm" in the diagram). Mice are gently placed in the region identified as "center" in the diagram, facing a closed arm, and allowed to freely explore the maze for one five minute interval. (B) Percent time spent in the open arms was calculated and compared among cohorts. (C) Visits to each region were also calculated, as was visit preference, calculated as the ratio of number of visits to the closed arms or the center and the number of visits to the open arms. (D) Percent time spent in the closed arms or center was calculated and compared among cohorts. (E) Distance moved and velocity of all mice during the test. Error bars represent the mean of biological replicates +/- SEM (n=10). Indicated p-values were calculated using two-tailed, unpaired, Student's t-test. $*p < 0.05$; ns, not significant.

Supplementary Figure 3. ISG expression, inflammasome activation, and glycolysis in BMDMs treated with GWICs.

Supplemental Figure 3. ISG expression, inflammasome activation, and glycolysis in BMDMs

treated with GWIC. (A) Western blot analysis of ISG expression in BMDMs treated with

overnight with GWIC, then treated with 200 ng/mL LPS for 6 or 24 hours as indicated. Cells

extracts were blotted for indicated proteins as in Figure 2. (B) and (C) Glycolysis as measured by

extracellular acidification rate (ECAR) in BMDMs treated with GWIC. BMDMs were treated

overnight with GWIC as indicated. Cells were treated with Seahorse medium (Mock) (B) or 200

ng/mL LPS (LPS) for 6 hours (C), then ECAR was measured on a Seahorse XF96 Analyzer using

a modified protocol as described in Section 2.8 of materials and methods. Error bars represent the

mean of technical replicates +/- SD (n=5). Significance values for pairwise comparisons were

calculated using the two-stage step-up method to yield q values that have been corrected for the

false discovery rate. * $q < 0.05$; ** $q < 0.01$; *** $q < 0.001$; **** $q < 0.0001$.

Supplemental Figure 4. Addition neurobehavioral tests performed on DMSO- and GWIC-exposed NLRP3$^{-/-}$·STING$^{gt/gt}$ C57BL/6 female mice.

Supplemental Figure 4. Additional neurobehavioral tests performed on DMSO- and GWIC-

exposed NLRP3$^{-/-}$ and STING$^{gt/gt}$ C57BL/6 female mice. (A) Results of OLT testing on DMSO-

and GWIC-exposed female NLRP3$^{-/-}$and STING$^{gt/gt}$ mice at 12 months post-exposure and DMSO-

and GWIC-exposed male NLRP3$^{-/-}$and STING$^{gt/gt}$ mice at 5 and 12 months post-exposure.

Experiments were performed as in Figure 1. (B) Results of NORT testing on DMSO- and GWIC-

exposed female NLRP3$^{-/-}$and STING$^{gt/gt}$ mice at 12 months post-exposure and DMSO- and GWIC-

exposed male NLRP3$^{-/-}$and STING$^{gt/gt}$ mice at 5 and 12 months post-exposure. Experiments were

performed as in Figure 1. (C) Results of PST testing on DMSO- and GWIC-exposed female and

male NLRP3$^{-/-}$and STING$^{gt/gt}$ mice at 5 and 12 months post-exposure. Experiments were

performed as in Figure 1. (D) Results of EPMT testing on DMSO- and GWIC-exposed female and

male NLRP3$^{-/-}$and STING$^{gt/gt}$ mice at 5 months post-exposure. Experiments were performed as in

Supplemental Figure 2. Error bars represent the mean of biological replicates +/- SEM (n=5-10 for

STING$^{gt/gt}$ females and 3-6 for STING$^{gt/gt}$ males, n=5-10 for NLRP3$^{-/-}$females and 3-7 for NLRP3^{-}

$^{/-}$males). Indicated p-values were calculated using two-tailed, unpaired, Student's t-test. * $p < 0.05$;

** $p < 0.01$; **** $p < 0.0001$, ns, not significant.

Supplemental Figure 5. Control data for OLT (object location test), PST (pattern separation test), and NORT (novel object recognition test) experiments depicted in Figures 5 and 6: total object exploration time, distance moved, and velocity for STING$^{gt/gt}$ and NLRP3$^{-/-}$ mice.

STING$^{gt/gt}$

Object Location Test
5 months

Object Location Test
12 months

Pattern Separation Test
5 months

Novel Object Recognition Test
5 months

Novel Object Recognition Test
12 months

Supplemental Figure 5. Control data for OLT (object location test), PST (pattern separation test), and NORT (novel object recognition test) experiments depicted in Figures 5 and 6: total object exploration time, distance moved, and velocity for STING$^{gt/gt}$ and NLRP3$^{-/-}$ mice.

NLRP3$^{-/-}$

**Object Location Test
5 months**

**Object Location Test
12 months**

**Pattern Separation Test
5 months**

**Novel Object Recognition Test
5 months**

**Novel Object Recognition Test
12 months**

Supplemental Figure 5. Control data for OLT (object location test), PST (pattern separation

test), and NORT (novel object recognition test): total object exploration time, distance

moved, and velocity for STING$^{gt/gt}$ and NLRP3$^{-/-}$ mice. For the OLT, PST, and NORT data

depicted in Figures 5, 6, and Supplemental Figure 4, data were collected on total object exploration

time (seconds), distance moved (meters), and velocity (centimeters per second) of all mice for all

three tests (object location test, OLT; pattern separation test, PST; novel object recognition test,

NORT). Error bars represent the mean of biological replicates +/- SEM (n=5-10 for STING$^{gt/gt}$

females and 3-6 for STING$^{gt/gt}$ males, n=5-10 for NLRP3$^{-/-}$females and 3-7 for NLRP3$^{-/-}$males).

Indicated p-values were calculated using one-way ANOVA with Tukey's multiple comparisons.

$*p < 0.05$; $**p < 0.01$; ns, not significant.

Supplementary Figure 6. Percent fraction of GFAP+ cells and GFAP expression in the hippocampi of NLRP3$^{-/-}$ and STING$^{gt/gt}$ GWIC-exposed female mice

Supplemental Figure 6. Percent fraction of GFAP+ cells and GFAP expression in the

hippocampi of NLRP3^{-/-} and STING^{gt/gt} female mice. (A) Quantification of percent fraction

GFAP+ cells within two regions of the hippocampus (the CA1 and CA3) in DMSO-exposed WT

female mice and GWIC-exposed WT, NLRP3$^{-/-}$ and STING$^{gt/gt}$ female mice. Error bars represent

the mean of biological replicates +/- SEM (n=6). Indicated p-values were calculated using two-

tailed, unpaired, Student's t-test. ***$p < 0.001$; **** $p < 0.0001$. (B) Images show representative

distribution and morphology of GFAP+ astrocytes in these three regions in female GWIC-exposed

WT, NLRP3$^{-/-}$ and STING$^{gt/gt}$ mice (scale bar = 100 µM). Insets show magnified views (scale bar

= 50 µM). (C) Tissue extracts were generated from microdissected hippocampi from DMSO-

exposed WT, NLRP3$^{-/-}$ and STING$^{gt/gt}$ mice and immunoblotted for GFAP as described in

Materials and Methods. Each lane represents one mouse, with n=3 for each genotype and sex.

Supplementary Figure 7. Analysis and imaging of IBA-1+ cells in the hippocampi of WT, NLRP3$^{-/-}$ and STING$^{gt/gt}$ mice.

Supplemental Figure 7. Analysis and imaging of IBA-1+ cells in the hippocampi of WT, NLRP3$^{-/-}$ and STING$^{gt/gt}$ mice. (A) Quantification of percent IBA-1+ cells with activated morphology in three hippocampal regions (DG, CA1, and CA3) in DMSO- and GWIC-exposed WT and GWIC-exposed NLRP3$^{-/-}$ and STING$^{gt/gt}$ female and male mice. Sections were scored blindly for total number of IBA-1+ cells and number of IBA-1+ cells with activated morphology. Error bars represent the mean of biological replicates +/- SEM (n=6). Indicated p-values were calculated using two-tailed, unpaired, Student's t-test. *$p < 0.05$; **$p < 0.01$; **** $p < 0.0001$. Absence of statistical information indicates a lack of statistical significance. **(B)** Images show representative distribution and morphology of IBA-1+ microglia in the DG region of female DMSO- and GWIC-exposed WT, and GWIC-exposed NLRP3$^{-/-}$ and STING$^{gt/gt}$ mice (scale bar = 100 µM). Insets show magnified views (scale bar = 50 µM).

References

1. Golomb, B. A. Acetylcholinesterase inhibitors and Gulf War illnesses. *Proc. Natl. Acad. Sci.*

U. S. A. **105**, 4295–4300 (2008).

2. White, R. F. *et al.* Recent research on Gulf War illness and other health problems in veterans of

the 1991 Gulf War: Effects of toxicant exposures during deployment. *Cortex J. Devoted Study*

Nerv. Syst. Behav. **74**, 449–475 (2016).

3. Shetty, G. A. *et al.* Chronic Oxidative Stress, Mitochondrial Dysfunction, Nrf2 Activation and

Inflammation in the Hippocampus Accompany Heightened Systemic Inflammation and

Oxidative Stress in an Animal Model of Gulf War Illness. *Front. Mol. Neurosci.* **10**, (2017).

4. Koslik, H. J., Hamilton, G. & Golomb, B. A. Mitochondrial dysfunction in Gulf War illness

revealed by 31Phosphorus Magnetic Resonance Spectroscopy: a case-control study. *PloS One*

9, e92887 (2014).

5. Golomb, B. A. *et al.* Coenzyme Q10 benefits symptoms in Gulf War veterans: results of a

randomized double-blind study. *Neural Comput.* **26**, 2594–2651 (2014).

6. Chen, Y. *et al.* Role of mitochondrial DNA damage and dysfunction in veterans with Gulf War

Illness. *PLOS ONE* **12**, e0184832 (2017).

7. Abdullah, L. *et al.* Translational potential of long-term decreases in mitochondrial lipids in a

mouse model of Gulf War Illness. *Toxicology* **372**, 22–33 (2016).

8. Emmerich, T. *et al.* Phospholipid profiling of plasma from GW veterans and rodent models to

identify potential biomarkers of Gulf War Illness. *PLOS ONE* **12**, e0176634 (2017).

9. Zakirova, Z. *et al.* Complementary proteomic approaches reveal mitochondrial dysfunction,

immune and inflammatory dysregulation in a mouse model of Gulf War Illness. *PROTEOMICS*

– Clin. Appl. **11**, 1600190 (2017).

10.   Castro-Marrero, J. *et al.* Could mitochondrial dysfunction be a differentiating marker

848   between chronic fatigue syndrome and fibromyalgia? *Antioxid. Redox Signal.* **19**, 1855–1860

849   (2013).

850   11.   Zhang, Q. *et al.* Changes in immune parameters seen in Gulf War veterans but not in

851   civilians with chronic fatigue syndrome. *Clin. Diagn. Lab. Immunol.* **6**, 6–13 (1999).

852   12.   Johnson, G. J., Slater, B. C. S., Leis, L. A., Rector, T. S. & Bach, R. R. Blood Biomarkers

853   of Chronic Inflammation in Gulf War Illness. *PloS One* **11**, e0157855 (2016).

854   13.   Parkitny, L., Middleton, S., Baker, K. & Younger, J. Evidence for abnormal cytokine

855   expression in Gulf War Illness: A preliminary analysis of daily immune monitoring data. *BMC*

856   *Immunol.* **16**, 57 (2015).

857   14.   Broderick, G. *et al.* A pilot study of immune network remodeling under challenge in Gulf

858   War Illness. *Brain. Behav. Immun.* **25**, 302–313 (2011).

859   15.   Broderick, G. *et al.* Altered immune pathway activity under exercise challenge in Gulf War

860   Illness: an exploratory analysis. *Brain. Behav. Immun.* **28**, 159–169 (2013).

861   16.   Janulewicz, P. A. *et al.* The Gut-Microbiome in Gulf War Veterans: A Preliminary Report.

862   *Int. J. Environ. Res. Public. Health* **16**, (2019).

863   17.   Craddock, T. J. A. *et al.* Using gene expression signatures to identify novel treatment

864   strategies in gulf war illness. *BMC Med. Genomics* **8**, 36 (2015).

865   18.   Seth, R. K. *et al.* Gut DNA Virome Diversity and Its Association with Host Bacteria

866   Regulate Inflammatory Phenotype and Neuronal Immunotoxicity in Experimental Gulf War

867   Illness. *Viruses* **11**, (2019).

868   19.   West, A. P. Mitochondrial dysfunction as a trigger of innate immune responses and

869   inflammation. *Toxicology* **391**, 54–63 (2017).

20.   West, A. P., Shadel, G. S. & Ghosh, S. Mitochondria in innate immune responses. *Nat.*

Rev. Immunol. **11**, 389–402 (2011).

21.   Nakahira, K., Hisata, S. & Choi, A. M. K. The Roles of Mitochondrial Damage-Associated

Molecular Patterns in Diseases. *Antioxid Redox Signal* **23**, 1329–1350 (2015).

22.   Ojo, J. O. *et al.* Exposure to an organophosphate pesticide, individually or in combination

with other Gulf War agents, impairs synaptic integrity and neuronal differentiation, and is

accompanied by subtle microvascular injury in a mouse model of Gulf War agent exposure.

Neuropathol. Off. J. Jpn. Soc. Neuropathol. **34**, 109–127 (2014).

23.   Zakirova, Z. *et al.* A Chronic Longitudinal Characterization of Neurobehavioral and

Neuropathological Cognitive Impairment in a Mouse Model of Gulf War Agent Exposure.

Front. Integr. Neurosci. **9**, 71 (2015).

24.   Zakirova, Z. *et al.* Gulf War agent exposure causes impairment of long-term memory

formation and neuropathological changes in a mouse model of Gulf War Illness. *PLoS ONE* **10**,

0119579 (2015).

25.   Heboyan, V. *et al.* Sex Differences in Gulf War Illness: A Reanalysis of Data From the

CDC Air Force Study Using CDC and Modified Kansas Case Definitions. *J. Occup. Environ.*

Med. **61**, 610–616 (2019).

26.   Fernández-Arjona, M. D. M., Grondona, J. M., Granados-Durán, P., Fernández-Llebrez,

P. & López-Ávalos, M. D. Microglia Morphological Categorization in a Rat Model of

Neuroinflammation by Hierarchical Cluster and Principal Components Analysis. *Front. Cell.*

Neurosci. **11**, 235 (2017).

27.   Hattiangady, B. *et al.* Object location and object recognition memory impairments,

892   motivation deficits and depression in a model of Gulf War illness. *Front. Behav. Neurosci.* **8**,

893   78 (2014).

894   28.   Parihar, V. K., Hattiangady, B., Shuai, B. & Shetty, A. K. Mood and memory deficits in a

895   model of Gulf War illness are linked with reduced neurogenesis, partial neuron loss, and mild

896   inflammation in the hippocampus. *Neuropsychopharmacol. Off. Publ. Am. Coll.*

897   *Neuropsychopharmacol.* **38**, 2348–2362 (2013).

898   29.   Zakirova, Z. *et al.* A Chronic Longitudinal Characterization of Neurobehavioral and

899   Neuropathological Cognitive Impairment in a Mouse Model of Gulf War Agent Exposure.

900   *Front. Integr. Neurosci.* **9**, 71 (2015).

901   30.   Kelly, B. & O'Neill, L. A. Metabolic reprogramming in macrophages and dendritic cells

902   in innate immunity. *Cell Res.* **25**, 771–784 (2015).

903   31.   Alhasson, F. *et al.* Altered gut microbiome in a mouse model of Gulf War Illness causes

904   neuroinflammation and intestinal injury via leaky gut and TLR4 activation. *PLoS ONE* **12**,

905   (2017).

906   32.   Gao, D. *et al.* Cyclic GMP-AMP Synthase is an Innate Immune Sensor of HIV and Other

907   Retroviruses. *Science* **341**, (2013).

908   33.   Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cGAS-STING pathway of

909   cytosolic DNA sensing. *Nat Immunol* **17**, 1142–1149 (2016).

910   34.   Elliott, E. I. & Sutterwala, F. S. Initiation and perpetuation of NLRP3 inflammasome

911   activation and assembly. *Immunol Rev* **265**, 35–52 (2015).

912   35.   Man, S. M. & Kanneganti, T.-D. Converging roles of caspases in inflammasome activation,

913   cell death and innate immunity. *Nat Rev Immunol* **16**, 7–21 (2016).

36.   Sauer, J.-D. *et al.* The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals

an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and

cyclic dinucleotides. *Infect. Immun.* **79**, 688–694 (2011).

37.   Kovarova, M. *et al.* NLRP1-dependent pyroptosis leads to acute lung injury and morbidity

in mice. *J. Immunol. Baltim. Md 1950* **189**, 2006–2016 (2012).

38.   Abdullah, L. *et al.* Lipidomic profiling of phosphocholine-containing brain lipids in mice

with sensorimotor deficits and anxiety-like features after exposure to Gulf War agents.

Neuromolecular Med. **14**, 349–361 (2012).

39.   Joshi, U. *et al.* Oleoylethanolamide treatment reduces neurobehavioral deficits and brain

pathology in a mouse model of Gulf War Illness. *Sci. Rep.* **8**, 12921 (2018).

40.   Joshi, U. *et al.* Targeting sirtuin activity with nicotinamide riboside reduces

neuroinflammation in a GWI mouse model. *Neurotoxicology* **79**, 84–94 (2020).

41.   Abdullah, L. *et al.* Proteomic CNS profile of delayed cognitive impairment in mice

exposed to Gulf War agents. *Neuromolecular Med.* **13**, 275–288 (2011).

42.   Kodali, M. *et al.* Curcumin treatment leads to better cognitive and mood function in a

model of Gulf War Illness with enhanced neurogenesis, and alleviation of inflammation and

mitochondrial dysfunction in the hippocampus. *Brain. Behav. Immun.* **69**, 499–514 (2018).

43.   Madhu, L. N. *et al.* Neuroinflammation in Gulf War Illness is linked with HMGB1 and

complement activation, which can be discerned from brain-derived extracellular vesicles in the

blood. *Brain. Behav. Immun.* **81**, 430–443 (2019).

44.   Shetty, A. K. *et al.* Monosodium luminol reinstates redox homeostasis, improves cognition,

mood and neurogenesis, and alleviates neuro- and systemic inflammation in a model of Gulf

War Illness. *Redox Biol.* **28**, 101389 (2020).

45.   Patten, E. & Parker, K. Women in the U.S. Military: Growing Share, Distinctive Profile.

6.

46.   Zundel, C. G. *et al.* Rates of Chronic Medical Conditions in 1991 Gulf War Veterans

Compared to the General Population. *Int. J. Environ. Res. Public. Health* **16**, (2019).

47.   Pierce, P. F. Federal Nursing Service AwardMonitoring the Health of Persian Gulf War

Veteran Women. *Mil. Med.* **170**, 349–354 (2005).

48.   Coughlin, S. S. *et al.* A Review of Epidemiologic Studies of the Health of Gulf War

Women Veterans. *J. Environ. Health Sci.* **3**, 0–0 (2017).

49.   Koslik, H. J., Hamilton, G. & Golomb, B. A. Mitochondrial Dysfunction in Gulf War

Illness Revealed by 31Phosphorus Magnetic Resonance Spectroscopy: A Case-Control Study.

PLOS ONE **9**, e92887 (2014).

50.   Chen, Y. *et al.* Role of mitochondrial DNA damage and dysfunction in veterans with Gulf

War Illness. *PLoS ONE* **12**, (2017).

51.   Zakirova, Z. *et al.* Complementary proteomic approaches reveal mitochondrial

dysfunction, immune and inflammatory dysregulation in a mouse model of Gulf War Illness.

Proteomics Clin. Appl. **11**, (2017).

52.   Butterick, T. A. *et al.* Gulf War Illness-associated increases in blood levels of interleukin

6 and C-reactive protein: biomarker evidence of inflammation. *BMC Res. Notes* **12**, (2019).

53.   Carpenter, J. M. *et al.* Neurochemical and neuroinflammatory perturbations in two Gulf

War Illness models: Modulation by the immunotherapeutic LNFPIII. *NeuroToxicology* **77**, 40–

50 (2020).

54.   Parkitny, L., Middleton, S., Baker, K. & Younger, J. Evidence for abnormal cytokine

expression in Gulf War Illness: A preliminary analysis of daily immune monitoring data. *BMC*

Immunol **16**, 57 (2015).

55.   Golomb, B. A. *et al.* Coenzyme Q10 Benefits Symptoms in Gulf War Veterans: Results of

a Randomized Double-Blind Study. *Neural Comput.* **26**, 2594–2651 (2014).

56.   Holodniy, M. & Kaiser, J. D. Treatment for Gulf War Illness (GWI) with KPAX002

(methylphenidate hydrochloride + GWI nutrient formula) in subjects meeting the Kansas case

definition: A prospective, open-label trial. *J. Psychiatr. Res.* **118**, 14–20 (2019).